Davangere Devanand, M.B.B.S., M.D.
Professor of Psychiatry and Neurology
Director, DIvision of Geriatric Psychiatry,
New York State Psychiatric Institute
Co-Director, Memory Disorders Center,
New York Presbyterian Hospital
Co-Director, Adult and Late Life Depression Clinic,
Davangere P. Devanand, M.D., is Director of the Division of Geriatric Psychiatry and Professor of Psychiatry and Neurology at the College of Physicians and Surgeons, Columbia University. He is also Co-Director of the Memory Disorders Center, and Co-Director of the Late Life Depression Clinic, at the New York State Psychiatric Institute.
Dr. Devanand completed medical school at Christian Medical College, Vellore, India, and psychiatry residency training at NIMHANS, Bangalore, India, S.U.N.Y. Upstate Medical Center, Syracuse, NY, and Yale University School of Medicine. After completing a clinical research fellowship at Columbia University he has remained on its faculty since 1987.
His research helped to define the clinical features and treatment response in elderly patients with dysthymic disorder, a chronic depressive illness. He pioneered studies on the interface between depression and cognitive impairment in the elderly, and is well-known for his research into early diagnostic markers of Alzheimer’s disease and the treatment of psychosis and agitation in this disorder. He has published research articles in major journals including the New England Journal of Medicine, JAMA, Archives of General Psychiatry, and American Journal of Psychiatry. He has been Principal Investigator on research grants from the National Institute of Aging, National Institute of Mental Health, Alzheimer’s Association, NARSAD, and the Dana Foundation. He was Chair of the Research Committee of the American Association of Geriatric Psychiatry. He received the International Psychogeriatrics Association Research Award and the Indo-American Psychiatric Association scientific research award. He is also the recipient of the American Psychiatric Association Jack Weinberg Memorial Award in Geriatric Psychiatry.
Dr. Devanand has over 240 research publications, and is the author of three books, including The Memory Program.
Medical School: Christian Medical College, Vellore, M.B.B.S., 1979
Doctoral Degree: State University of New York, M.D., 1985
Internship: SUNY Upstate Medical Center, Psychiatry Residency, 1980 - 1982
Residency: Yale, Psychiatry Residency, 1982 - 1984
Fellowship: Columbia University, Research Fellowship, 1985 - 1987
Board Certifications: American Board of Psychiatry and Neurology 1985
Subspeciality Certifications: Geriatric Psychiatry sub-specialty 1991, re-certified 2009
• Neuropsychiatry/Cognitive Disorders
• Depressive Disorders
Click here for Dr. Devanand's Clinical Trials
NYS Psychiatric Institute
Room 2726 Unit/Box:126
1051 Riverside Drive
New York, NY 10032
Research interests include treatment strategies for mild cognitive impairment and Alzheimer's disease, including treatment of psychosis and agitation in these disorders. Other interests include early diagnostic markers of Alzheimer's disease, and the interface between depression and cognitive impairment.
1. Devanand DP, Michaels-Marston KS, Liu X, Pelton GH, Padilla M, Marder K, Bell K, Stern Y, Mayeux R : Olfactory deficits in mild cognitive impairment predict Alzheimer's disease on follow-up. . American Journal of Psychiatry 2000;157: 1399-1405
1. Devanand DP, Pelton GH, Marston K, Camacho Y, Roose SP, Stern Y, Sackeim HA : Sertraline treatment of elderly patients with depression and cognitive impairment. . Int J Geriatr Psychiatry 2003;18: 123-130
1. Devanand DP, Pradhaban G, Khandji A, Tabert MH, De Santi S, Segal S, Liu X, Pelton GH, Honig L, Mayeux R, Stern Y, de Leon, M: Hippocampal and entorhinal atrophy in the prediction of MCI conversion to Alzheimer’s disease.. Neurology 2007;68: 828-836
1. Devanand DP, Liu X, Tabert MH, Pradhaban G, Cuasay K, Bell K, de Leon MJ, Doty RL, Stern Y, Pelton GH: Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biological Psychiatry 2008;64: 871-879
1. Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, Gupta S, Colon S, Schimming C, Pelton GH, Levin B: Relapse risk after discontinuation of risperidone in Alzheimer’s disease.. New England Journal of Medicine 2012;367: 1497-1507